Table 2.

Response rates in randomized trials comparing a liposomal anthracycline with ABV or BV ^{a, b}

	Stewart et al 1998			Northfelt et al 1998
	PLD (Doxil) (n = 121)	BV (n = 120)	P value	PLD (Doxil) (n = 133)	ABV (n = 125)	P value
CR, %	6	1	<0.001	1	0	NS
PR, %	53	22	<0.001	45	25	<0.001
CR + PR, % (95% CI)	59 (50–67)	23 (16–31)		46 (37–54)	25 (17–32)
Stable disease, %	38	68		53	67
Progressive disease, %	0	4		2	8
Not assessable, %	3	5		0	0

^aBest response during treatment.

^bPartial response defined as absence of new cutaneous or oral lesions, new visceral sites of involvement, or the appearance or worsening or tumor-associated edema or effusions plus at least one of the following: a 50% decrease in the sum of the products of the skin lesions, complete flattening of greater than 50% of all previously raised skin lesions, a 50% decrease in the sum of the products of the largest perpendicular diameters of prospectively selected indicator skin lesions, or the patient met the criteria for Complete Clinical Response, except that residual tumor-associated edema or effusion was present. The response was required to persist for at least 4 weeks.

Abbreviations: ABV, doxorubicin, bleomycin, vincristine; BV, bleomycin, vincristine; CR, complete response; PR, partial response; NS, not significant.